The Society
More than 35,000 clinicians, scientists and allied health professionals from over 160 countries are part of the ERS community
Become an ERS member
ERS is proud to be represented by leading specialists in the field of respiratory medicine and science. Between them, the Society’s leaders have a wealth of experience, knowledge and expertise covering a broad range of disease areas and professional specialties.
In the build-up to the ERS Congress 2025, each member of the ERS leadership team will tell us what they are looking forward to most about the Congress in Amsterdam and the sessions they highly recommend in this year’s Congress programme.
None
| Company | Purpose of Payment | Amount of funds received* |
|---|---|---|
| Irish Rugby Football Union | Ad hoc Consultancy work | A |
| American College of Cardiology | Content Development | B |
None
None
| Company | Nature of Support | Amount of funds received* |
|---|---|---|
| NovoNordisk | Unrestricted grant | D |
| Fitbit | Unrestricted grant | D |
None
No. I declare that I have not been full or part time employee of, paid consultant or advisor to /received a grant from the tobacco industry at any time after 1.1.2000, for any project or programme.
| A | B | C | D |
|---|---|---|---|
| less than € 1'000 | € 1001 - € 5'000 | € 5'001 - € 20'000 | more than € 20'000 |
None
| Company | Purpose of Payment | Amount of funds received* |
|---|---|---|
| CSL Behring | lectures | B |
| Grifols | jury of the "Annual ALTA (Alpha-1-Antitrypsin Laurell’s Training Awards) 2025" | B |
| Sanofi | lectures, advisory board | B |
| Amgen | lectures, congress participation | B |
| Chiesi | lectures, congress participation | B |
| Pfizer | lectures | B |
| Amgen | lectures | B |
| Chiesi | lectures | B |
| Company | Purpose and Nature of Benefit | Amount of funds received* |
|---|---|---|
| Chiesi | travel grant | B |
| Amgen | travel grant | B |
None
None
None
No. I declare that I have not been full or part time employee of, paid consultant or advisor to /received a grant from the tobacco industry at any time after 1.1.2000, for any project or programme.
| A | B | C | D |
|---|---|---|---|
| less than € 1'000 | € 1001 - € 5'000 | € 5'001 - € 20'000 | more than € 20'000 |
None
| Company | Purpose of Payment | Amount of funds received* |
|---|---|---|
| various universities | Reviews, PhD defences | A |
| various teaching institutions | lectures outside my home university | A |
| Company | Purpose and Nature of Benefit | Amount of funds received* |
|---|---|---|
| ERS | various conferences in my function as advocacy chair | C |
None
| Company | Nature of Support | Amount of funds received* |
|---|---|---|
| DFG | Research grant | D |
| BMBF | Research grant | D |
| German Environment Agency | Research grant | D |
None
No. I declare that I have not been full or part time employee of, paid consultant or advisor to /received a grant from the tobacco industry at any time after 1.1.2000, for any project or programme.
| A | B | C | D |
|---|---|---|---|
| less than € 1'000 | € 1001 - € 5'000 | € 5'001 - € 20'000 | more than € 20'000 |
None
| Company | Purpose of Payment | Amount of funds received* |
|---|---|---|
| AstraZeneca | Presentations, advisory boards | C |
| GSK | Presentations, advisory boards | C |
| Chiesi | Presentations, advisory boards | C |
| Sanofi | Presentations, advisory boards | C |
| Roche | Consultation | B |
| Ménarini | Presentation | A |
| Pfizer | Consultation | B |
| Boehringer Ingelheim | Education | A |
| Company | Purpose and Nature of Benefit | Amount of funds received* |
|---|---|---|
| Sanofi | French Respiratory Society Congress | A |
None
| Company | Nature of Support | Amount of funds received* |
|---|---|---|
| GSK | Research grant | C |
| Pfizer | Research grant | C |
None
No. I declare that I have not been full or part time employee of, paid consultant or advisor to /received a grant from the tobacco industry at any time after 1.1.2000, for any project or programme.
| A | B | C | D |
|---|---|---|---|
| less than € 1'000 | € 1001 - € 5'000 | € 5'001 - € 20'000 | more than € 20'000 |